Perimenopause and EDS/Hypermobility: Why the Transition Is So Hard on Connective Tissue

Introduction

For women with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD), perimenopause is often described as one of the most difficult periods of their lives. Joint instability worsens. Pain increases. Fatigue becomes more profound. POTS and MCAS symptoms that were previously manageable can become disabling. And the standard reassurance that "this is just menopause" fails to capture the severity of what these women are experiencing.

The reason perimenopause is so challenging for hypermobile patients is not simply hormonal — it is structural. Estrogen plays a critical role in maintaining connective tissue integrity, and its decline during perimenopause directly worsens the collagen abnormalities that underlie hEDS and HSD.

---

Estrogen and Connective Tissue

Estrogen has multiple effects on connective tissue that are directly relevant to hEDS and HSD:

Collagen synthesis and quality

Estrogen stimulates collagen synthesis in fibroblasts — the cells responsible for producing the extracellular matrix. It also promotes the cross-linking of collagen fibers, which is essential for tensile strength and stability. When estrogen declines, collagen synthesis decreases and cross-linking is impaired, resulting in:

• Reduced tensile strength in ligaments, tendons, and joint capsules
• Increased joint laxity — joints that were already hypermobile become even more unstable
• Reduced skin thickness and elasticity — the skin changes of menopause reflect the same connective tissue changes affecting joints
• Increased injury risk — tendons and ligaments are more prone to strain and tear

Relaxin and the menstrual cycle

Relaxin — a hormone that increases joint laxity — fluctuates across the menstrual cycle, peaking around ovulation. Many hEDS patients notice increased joint instability and pain around ovulation, consistent with relaxin's effects. During perimenopause, the irregular hormonal fluctuations can produce unpredictable relaxin spikes, contributing to variable joint stability.

Mast cell effects

As discussed in the estrogen-MCAS article, estrogen modulates mast cell activity. Mast cells are present throughout connective tissue and release mediators (tryptase, histamine, prostaglandins) that degrade the extracellular matrix and promote inflammation. The mast cell destabilization of perimenopause can worsen the connective tissue environment in hEDS patients.

---

The Perimenopause-hEDS Symptom Cascade

The worsening of hEDS during perimenopause is not a single symptom — it is a cascade of interconnected changes:

Increased joint instability → more subluxations and dislocations → more pain → more protective muscle guarding → more fatigue → reduced activity → deconditioning → further instability

Worsened POTS (from estrogen decline) → more orthostatic symptoms → reduced activity tolerance → deconditioning → worsened POTS

Worsened MCAS (from mast cell destabilization) → more inflammation → more connective tissue degradation → more pain → more fatigue

Sleep disruption (from perimenopausal insomnia and pain) → reduced recovery → increased pain sensitivity → worsened all symptoms

These cascades interact and amplify each other, which is why perimenopause can feel so catastrophic for hEDS patients.

---

Specific Symptoms to Expect

Women with hEDS entering perimenopause should be prepared for potential worsening of:

---

Management Strategies

Hormone therapy

Estrogen therapy is the most direct intervention for perimenopause-related worsening in hEDS. By maintaining estrogen levels, HRT can:

• Preserve collagen synthesis and quality
• Reduce joint laxity progression
• Stabilize autonomic function (POTS)
• Stabilize mast cells (MCAS)

Transdermal estradiol is the preferred form. The dose should be sufficient to maintain physiological estrogen levels — not just the minimum to reduce hot flashes.

Bioidentical progesterone (for women with an intact uterus) is preferred over synthetic progestins, particularly for patients with MCAS.

The decision to use HRT should be made with a gynecologist or menopause specialist who is aware of the hEDS diagnosis and its implications.

Physical therapy and joint stabilization

As joint laxity worsens during perimenopause, physical therapy becomes even more important:

• Proprioceptive training — improving joint position sense to compensate for increased laxity
• Muscle strengthening — building the muscular support that compensates for ligamentous laxity
• Bracing and splinting — providing external joint support during vulnerable periods
• Activity modification — reducing high-impact activities that stress unstable joints

POTS management

Standard POTS management remains important and may need intensification during perimenopause:

• Increased sodium and fluid intake
• Compression garments
• Medication adjustments as needed

MCAS management

Mast cell stabilization becomes more important during perimenopause:

• Antihistamine optimization
• Mast cell stabilizers (cromolyn, ketotifen)
• Low-histamine diet during high-symptom periods
• Hormonal stabilization (as above)

Sleep and fatigue management

Perimenopausal sleep disruption compounds hEDS fatigue significantly:

• Address hot flashes and night sweats (HRT is most effective)
• Sleep hygiene optimization
• Low-dose tricyclic antidepressants for sleep architecture improvement
• Pacing to manage fatigue within available energy limits

---

Building a Care Team for Perimenopause with hEDS

Managing perimenopause with hEDS optimally requires a coordinated care team:

• Gynecologist or menopause specialist — for hormonal management
• Rheumatologist or geneticist — for hEDS management
• Cardiologist or autonomic specialist — for POTS
• Allergist or immunologist — for MCAS
• Physical therapist — for joint stabilization and pain management
• Pain specialist — if pain is not adequately controlled

---

Conclusion

Perimenopause is a particularly challenging transition for women with hEDS and HSD, but it is not insurmountable. Understanding why the transition is so difficult — the role of estrogen in connective tissue, autonomic function, and mast cell stability — allows for proactive management rather than reactive crisis management.

Hormone therapy, when appropriate, can be transformative for hEDS patients in perimenopause. Combined with optimized physical therapy, POTS management, and MCAS management, it is possible to navigate this transition with significantly less suffering than many women with hEDS currently experience.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.